Concepts (84)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver | 7 | 2024 | 434 | 2.360 |
Why?
|
| Bile Acids and Salts | 6 | 2024 | 22 | 2.280 |
Why?
|
| Fibroblast Growth Factors | 3 | 2023 | 23 | 1.600 |
Why?
|
| Fatty Liver | 2 | 2024 | 57 | 1.580 |
Why?
|
| Hyperglycemia | 2 | 2024 | 78 | 1.550 |
Why?
|
| Thiazepines | 2 | 2021 | 4 | 1.460 |
Why?
|
| Methylamines | 2 | 2021 | 6 | 1.450 |
Why?
|
| Cholesterol | 2 | 2021 | 200 | 1.260 |
Why?
|
| Cullin Proteins | 2 | 2024 | 11 | 0.990 |
Why?
|
| Organic Anion Transporters, Sodium-Dependent | 2 | 2021 | 3 | 0.900 |
Why?
|
| Symporters | 2 | 2021 | 8 | 0.900 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 2 | 2022 | 15 | 0.890 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2024 | 25 | 0.870 |
Why?
|
| Mice | 9 | 2024 | 4645 | 0.830 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2024 | 67 | 0.820 |
Why?
|
| Glycine | 1 | 2023 | 31 | 0.820 |
Why?
|
| Cholestasis | 1 | 2023 | 11 | 0.810 |
Why?
|
| Amino Acids, Sulfur | 1 | 2022 | 2 | 0.800 |
Why?
|
| Insulin Resistance | 1 | 2024 | 176 | 0.780 |
Why?
|
| NEDD8 Protein | 1 | 2022 | 6 | 0.770 |
Why?
|
| Cyclopentanes | 1 | 2022 | 13 | 0.760 |
Why?
|
| Liver Diseases, Alcoholic | 1 | 2021 | 5 | 0.720 |
Why?
|
| Receptor, Insulin | 1 | 2022 | 94 | 0.710 |
Why?
|
| Pyrimidines | 1 | 2022 | 126 | 0.710 |
Why?
|
| Animals | 10 | 2024 | 10399 | 0.680 |
Why?
|
| Insulin | 1 | 2022 | 315 | 0.670 |
Why?
|
| Lipid Metabolism | 1 | 2021 | 133 | 0.670 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2021 | 67 | 0.660 |
Why?
|
| Mice, Inbred C57BL | 4 | 2024 | 1570 | 0.550 |
Why?
|
| Mice, Knockout | 3 | 2024 | 845 | 0.520 |
Why?
|
| Coenzyme A | 2 | 2024 | 11 | 0.420 |
Why?
|
| Cysteine | 2 | 2024 | 68 | 0.410 |
Why?
|
| Glutathione | 2 | 2024 | 72 | 0.410 |
Why?
|
| Ubiquitin-Protein Ligases | 2 | 2024 | 76 | 0.390 |
Why?
|
| Lipids | 2 | 2024 | 208 | 0.380 |
Why?
|
| Antioxidants | 2 | 2024 | 225 | 0.360 |
Why?
|
| Male | 6 | 2023 | 13487 | 0.330 |
Why?
|
| Cell Line | 2 | 2022 | 694 | 0.310 |
Why?
|
| Liver Cirrhosis | 2 | 2023 | 72 | 0.250 |
Why?
|
| Disease Models, Animal | 2 | 2021 | 1461 | 0.240 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2024 | 15 | 0.220 |
Why?
|
| Cysteine Dioxygenase | 1 | 2024 | 1 | 0.220 |
Why?
|
| Taurine | 1 | 2024 | 9 | 0.220 |
Why?
|
| Acetaminophen | 1 | 2024 | 11 | 0.220 |
Why?
|
| Hepatocytes | 1 | 2024 | 78 | 0.210 |
Why?
|
| NAD | 1 | 2024 | 100 | 0.210 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2024 | 121 | 0.200 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2023 | 24 | 0.200 |
Why?
|
| Methionine Adenosyltransferase | 1 | 2022 | 3 | 0.200 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2022 | 40 | 0.200 |
Why?
|
| Cystine | 1 | 2022 | 6 | 0.200 |
Why?
|
| Methionine | 1 | 2022 | 37 | 0.200 |
Why?
|
| Dietary Proteins | 1 | 2022 | 35 | 0.200 |
Why?
|
| Fibrosis | 1 | 2023 | 133 | 0.190 |
Why?
|
| Ubiquitins | 1 | 2022 | 7 | 0.190 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2022 | 60 | 0.190 |
Why?
|
| Ubiquitination | 1 | 2022 | 32 | 0.190 |
Why?
|
| Homeostasis | 1 | 2022 | 117 | 0.190 |
Why?
|
| Angiogenic Proteins | 1 | 2021 | 4 | 0.180 |
Why?
|
| Transaminases | 1 | 2021 | 10 | 0.180 |
Why?
|
| Oxidation-Reduction | 1 | 2022 | 362 | 0.180 |
Why?
|
| Dependovirus | 1 | 2021 | 16 | 0.180 |
Why?
|
| Fructose | 1 | 2021 | 22 | 0.180 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2021 | 19 | 0.180 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 58 | 0.180 |
Why?
|
| Genetic Vectors | 1 | 2021 | 116 | 0.170 |
Why?
|
| Cholesterol 7-alpha-Hydroxylase | 1 | 2020 | 1 | 0.170 |
Why?
|
| Hypercholesterolemia | 1 | 2020 | 18 | 0.170 |
Why?
|
| Hep G2 Cells | 1 | 2020 | 31 | 0.170 |
Why?
|
| Ileum | 1 | 2020 | 25 | 0.170 |
Why?
|
| Combined Modality Therapy | 1 | 2021 | 302 | 0.170 |
Why?
|
| Genetic Therapy | 1 | 2021 | 123 | 0.170 |
Why?
|
| Diet, Western | 1 | 2020 | 28 | 0.170 |
Why?
|
| Oxidative Stress | 1 | 2024 | 663 | 0.160 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 451 | 0.150 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 633 | 0.140 |
Why?
|
| Humans | 3 | 2023 | 28121 | 0.130 |
Why?
|
| Signal Transduction | 1 | 2022 | 1433 | 0.120 |
Why?
|
| Treatment Outcome | 1 | 2021 | 2380 | 0.110 |
Why?
|
| Female | 2 | 2023 | 15156 | 0.080 |
Why?
|
| Hepatic Stellate Cells | 1 | 2022 | 14 | 0.050 |
Why?
|
| Estradiol | 1 | 2022 | 175 | 0.050 |
Why?
|
| Collagen | 1 | 2022 | 156 | 0.050 |
Why?
|
| Longevity | 1 | 2022 | 134 | 0.050 |
Why?
|